411 related articles for article (PubMed ID: 23592171)
1. Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry.
Gawlick U; Lu KC; Douthit MA; Diggs BS; Schuff KG; Herzig DO; Tsikitis VL
Am J Surg; 2013 May; 205(5):608-12; discussion 612. PubMed ID: 23592171
[TBL] [Abstract][Full Text] [Related]
2. Mutational analysis and clinical correlation of metastatic colorectal cancer.
Russo AL; Borger DR; Szymonifka J; Ryan DP; Wo JY; Blaszkowsky LS; Kwak EL; Allen JN; Wadlow RC; Zhu AX; Murphy JE; Faris JE; Dias-Santagata D; Haigis KM; Ellisen LW; Iafrate AJ; Hong TS
Cancer; 2014 May; 120(10):1482-90. PubMed ID: 24500602
[TBL] [Abstract][Full Text] [Related]
3. Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas.
Kalady MF; Sanchez JA; Manilich E; Hammel J; Casey G; Church JM
Dis Colon Rectum; 2009 Jun; 52(6):1039-45. PubMed ID: 19581844
[TBL] [Abstract][Full Text] [Related]
4. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
[TBL] [Abstract][Full Text] [Related]
5. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
6. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
[TBL] [Abstract][Full Text] [Related]
7. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
8. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
[TBL] [Abstract][Full Text] [Related]
9. Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.
Reggiani Bonetti L; Barresi V; Bettelli S; Caprera C; Manfredini S; Maiorana A
Hum Pathol; 2017 Apr; 62():91-98. PubMed ID: 28025078
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations.
Ogura T; Kakuta M; Yatsuoka T; Nishimura Y; Sakamoto H; Yamaguchi K; Tanabe M; Tanaka Y; Akagi K
Oncol Rep; 2014 Jul; 32(1):50-6. PubMed ID: 24806883
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer.
Foltran L; De Maglio G; Pella N; Ermacora P; Aprile G; Masiero E; Giovannoni M; Iaiza E; Cardellino GG; Lutrino SE; Mazzer M; Giangreco M; Pisa FE; Pizzolitto S; Fasola G
Future Oncol; 2015; 11(4):629-40. PubMed ID: 25686118
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.
Barault L; Veyrie N; Jooste V; Lecorre D; Chapusot C; Ferraz JM; Lièvre A; Cortet M; Bouvier AM; Rat P; Roignot P; Faivre J; Laurent-Puig P; Piard F
Int J Cancer; 2008 May; 122(10):2255-9. PubMed ID: 18224685
[TBL] [Abstract][Full Text] [Related]
14. Role of oncogenic pathways and KRAS/BRAF mutations in the behavior of colon adenocarcinoma in renal transplant patients.
Revuelta I; Moya-Rull D; García-Herrera A; Rovira J; Ayala de la Peña F; Misiego A; Guzmán F; Oppenheimer F; Albanell J; Campistol JM
Transplantation; 2012 Mar; 93(5):509-17. PubMed ID: 22245873
[TBL] [Abstract][Full Text] [Related]
15. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.
Tie J; Lipton L; Desai J; Gibbs P; Jorissen RN; Christie M; Drummond KJ; Thomson BN; Usatoff V; Evans PM; Pick AW; Knight S; Carne PW; Berry R; Polglase A; McMurrick P; Zhao Q; Busam D; Strausberg RL; Domingo E; Tomlinson IP; Midgley R; Kerr D; Sieber OM
Clin Cancer Res; 2011 Mar; 17(5):1122-30. PubMed ID: 21239505
[TBL] [Abstract][Full Text] [Related]
16. Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas.
Crumley SM; Pepper KL; Phan AT; Olsen RJ; Schwartz MR; Portier BP
Arch Pathol Lab Med; 2016 Jun; 140(6):529-35. PubMed ID: 26536055
[TBL] [Abstract][Full Text] [Related]
17. KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer.
Kohonen-Corish MR; Tseung J; Chan C; Currey N; Dent OF; Clarke S; Bokey L; Chapuis PH
Int J Cancer; 2014 Jun; 134(12):2820-8. PubMed ID: 24259266
[TBL] [Abstract][Full Text] [Related]
18. Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.
Sclafani F; Wilson SH; Cunningham D; Gonzalez De Castro D; Kalaitzaki E; Begum R; Wotherspoon A; Capdevila J; Glimelius B; Roselló S; Thomas J; Tait D; Brown G; Oates J; Chau I
Int J Cancer; 2020 Jan; 146(1):94-102. PubMed ID: 31199501
[TBL] [Abstract][Full Text] [Related]
19. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
Ogino S; Liao X; Imamura Y; Yamauchi M; McCleary NJ; Ng K; Niedzwiecki D; Saltz LB; Mayer RJ; Whittom R; Hantel A; Benson AB; Mowat RB; Spiegelman D; Goldberg RM; Bertagnolli MM; Meyerhardt JA; Fuchs CS;
J Natl Cancer Inst; 2013 Dec; 105(23):1789-98. PubMed ID: 24231454
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer.
Lochhead P; Imamura Y; Morikawa T; Kuchiba A; Yamauchi M; Liao X; Qian ZR; Nishihara R; Wu K; Meyerhardt JA; Fuchs CS; Ogino S
Eur J Cancer; 2012 Dec; 48(18):3405-13. PubMed ID: 22840368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]